


Opioid Dependence Treatment Program (ODTP) Reforms Pharmacists Fact Sheet



Reforms to the Opioid Dependence Treatment Program (ODTP) will come into effect on 1 July 2023. HRA has compiled this fact sheet for community and hospital pharmacists to provide an overview of the reforms and their implications for pharmacy:

1. Changes to PBS listing arrangements:

- From **1 July 2023** the way ODT medicines are listed on the PBS Schedule is changing.
 - The way ODT medicines **are prescribed, ordered, supplied (dispensed) and remunerated** will align with other medicines under the [Section 100 HSD Program \(Community Access\) arrangements](#).
- All existing clinics **will continue** to be able to treat and provide clinical services to patients, and they will be able to prescribe opioid treatment medicines, however they will **NOT be able to dispense** medicines under the PBS Section 100 HSD Program.
- Under the Section 100 HSD Program, ODT medicines can only be dispensed from:
 - a section 90 approved community pharmacy.
 - a section 94 public or private hospital.
 - a section 92 dispensing doctor.

2. Changes to service fees and payment arrangements:

- From 1 July 2023 nationally consistent payment arrangements for ODT services delivered through community pharmacy will be introduced which will mean less out-of-pocket costs for ODTP consumers.
- PBS-eligible patients will pay the [PBS co-payment](#) (\$30.00 for general patients and \$7.30 for concession card holders) for up to 28 days' supply per pharmaceutical benefit.



- The amount paid will contribute towards the patients [PBS Safety Net threshold](#).
- **No additional private dispensing or dosing administration fees can be charged** by section 90 or section 94 approved pharmacies to patients for access to ODT medicines under the PBS.
- From 1 July 2023, a new **ODT Community Pharmacy Program** will be established and administered by the [Pharmacy Programs Administrator \(PPA\)](#) and is designed to complement the new PBS listing arrangements for ODT medications.
- A new ODT staged supply service fee and buprenorphine injection fee will be available to section 90 approved community pharmacies.
- ODT Staged Supply dose management fee is equivalent to the current [Seventh Community Pharmacy Agreement Staged Supply Program](#) fee **plus** an added consumables allowance.
 - NO cap on the number of eligible patients claimed/month (although state/territory limits on numbers of patients each pharmacy can service, will still apply).
- ODT Community Pharmacy Program fees can **ONLY** be claimed by section 90 approved community pharmacies - Section 94 hospital pharmacies are **NOT** eligible.
- From 1 July 2023, section 90 approved community pharmacies will need to:
 - Participate in the ODT Community Pharmacy Program through the PPA.
 - Submit PBS claims for reimbursement to [Services Australia](#).

3. Changes to ordering, dispensing, remuneration:

- **Ordering:**
 - Pharmacies can continue to order ODT medicines through their usual pharmaceutical distributor/wholesaler.
 - From 1 July 2023 ODT medicines will be purchased (**rather than ordered at no cost**) and are subject to the same arrangements as other Section 100 medicines.
 - ODT stock ordered prior to 1 July 2023 can continue to be used.
- **Dispensing:**
 - From 1 July 2023, like other PBS medicines, new prescriptions that are written by eligible prescribers for ODT medicines will need to meet the PBS requirements to be dispensed and claimed through Service Australia.
 - For detailed information on dispensing requirements and transitional arrangements for existing paper-based and electronic prescriptions see the [Department of Health & Aged Care fact sheet](#) including: *Box 2: Guide for pharmacists dispensing ODT medicines starting 1 July 2023 p.9.*

- **Fees & Remuneration:**
 - **PBS Fees:**
 - As part of the PBS claim, pharmacists are remunerated for the ex-manufacturer price of the drug dispensed.
 - In addition, for each pharmaceutical benefit dispensed, pharmacies will be reimbursed:
 - the normal PBS ready-prepared dispensing fee (\$8.37) +
 - the dangerous drug fee (\$5.18) per pharmaceutical benefit supplied +
 - an S100 mark-up (which is a percentage of the ex-manufacturer price of the drug and will vary depending on the cost of the drug).
 - Under the Section 100 HSD Program PBS approved public hospitals receive reimbursement for the approved ex-manufacturer price or the proportional ex-manufacturer price for each dispensed quantity (i.e., the cost of the drug).
 - **ODT Community Pharmacy Program Fees:**
 - In addition to the above PBS fees, under the ODT Community Pharmacy Program, section 90 approved community pharmacies participating in state and territory ODT programs will be able to:
 - submit claims for staged supply fees where the ODT medications have been dispensed under PBS arrangements.
 - submit claims for payment for on-site pharmacist administration of injectable weekly and monthly buprenorphine dispensed under PBS arrangements.
 - The community pharmacy program payments also include a container fee.

See Table 1 and Table 2 for more detailed breakdowns and examples of the PBS and ODT Community Pharmacy Program fees and payments for Section 90 community pharmacies.

Table 1. ODT Community Pharmacy Program Fees, 1 July 2023

Fees	Fee amount (per day)	Fee amount (28 days)
ODT Staged Supply Service Fee		
Dose management fee	\$4.69	\$131.32
Consumables allowance fee	\$0.97	\$27.16
Total	\$5.66	\$158.48 per patient
Buprenorphine Injection Administration Fee	-	\$22.15 per injection ¹

¹ E.g., on-site administration of a monthly injection (over 28 days): 1x \$22.15 administration fee.
Administration of 4 weekly injections (over 28 days): 4 x \$22.15 = \$88.60 in administration fees.

(Taken from DoHA, ODT claiming and payment arrangements for community pharmacies - 19 June 2023)

Table 2. Examples of PBS fees and ODT Community Pharmacy Program fees for the supply of ODT medicines from section 90 approved community pharmacies.

Note: As part of the PBS claim, pharmacists are also remunerated for the approved ex-manufacturer price (AEMP) (i.e., the cost of the drug) for the dispensed quantity.

ODT medicine prescribed / quantity (28 days)	PBS dispensing fees ¹	ODT Staged supply fee ² (28 days)	Buprenorphine injection administration fee ³	Total fees (excluding AEMP and PBS co-payment)	AEMP
Methadone liquid, 5mg/ml, 28 days' supply (max qty) Dispensed from 1L bottle	\$16.34	\$158.48	N/A	\$174.82	\$27.89
Buprenorphine sublingual tablets, 8mg, 28 days' supply (max qty)	\$28.91	\$158.48	N/A	\$187.39	\$383.84
Buprenorphine with Naloxone Sublingual films, 10mg, 28 days' supply (10mg daily dose) (Prescribed as one qty of 8mg films + one qty of 2mg films)	\$33.72	\$158.48	N/A	\$192.20	2mg film: \$46.20 8mg film: \$119.20
Buprenorphine weekly injections, 28 days' supply (max qty)	\$27.59	N/A	\$88.60	\$116.19	\$351.12
Buprenorphine monthly injection, 28 days' supply (max qty)	\$27.59	N/A	\$22.15	\$49.74	\$351.12

¹ 1 July 2023 PBS S100 HSD Program fees - ready-prepared dispensing fee (\$8.37) + s100 mark-up + dangerous drug fee (\$5.18)

² ODT Staged Supply/Dose management fee (\$4.69 per day) + consumables allowance fee (\$0.97 per day) = \$5.66. Applies equally for in-pharmacy and take-away doses.

³ Buprenorphine injections: \$22.15 per injection i.e. 1 x monthly injection (28 days) = \$22.15; weekly injections (4 x injections for 28 days) = \$88.60

(Taken from DoHA, ODT claiming and payment arrangements for community pharmacies - 19 June 2023)